ClinicaliQ Trial Snapshot
- A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia — Recruiting • Phase I • Oncology • NCT07295951.
- What is being tested: Pharmacokinetic and metabolic profiling of radiolabeled bleximenib using radioactive carbon-14 tracing to determine absorption, metabolism, and excretion pathways in acute leukemia patients.
- Patient eligibility overview: The trial enrolls adult participants with confirmed acute leukemia diagnoses who meet specific safety and organ function criteria, with detailed screening to ensure suitability for radioactive compound administration.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).
Eligibility Snapshot
- : * Body weight greater than or equal to (>=) 40 kilograms (kg) * Relapsed or refractory (R/R) acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A), nucleophosmin 1 (NPM1), nucleoporin 98 (NUP98) or nucleoporin 214 (NUP214) gene alterations, and has exhausted, or is ineligible for available therapeutic options * Eastern cooperative oncology group (ECOG) performance status grade of 0 or 1 * Regular bowel movements (that is [i.e.], average production of at least one stool every 2 days) * A woman of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.